OPKO Health Stock Rises Sharply on NFL Coronavirus Testing Deal
Investors were cheered by the healthcare company's latest coronavirus testing deal in the professional sports arena. Jon Cohen, the executive chairman of the company's busy BioReference Laboratories diagnostics subsidiary, disclosed in a TV interview Monday on CNBC's Mad Money that BioReference had agreed in principle with the National Football League to provide coronavirus testing for all 32 of its teams. In a subsequent regulatory filing, OPKO wrote that "[t]he foregoing agreement in principle with the NFL remains subject to definitive documentation and the parties' execution and delivery thereof."
